Bioequivalence data fabrication haunts drug makers

The controversy over the bioequivalence data fabrication will flare again the Korea Medical Association plans to make public about a list of 500 medicines whose bioequivalence data were manipulated in collaboration with the research centers.

The KPA said that it will unveil the list on June 28 to ensure people’s right to know.

Market watchers predict the impact of the data fabrication on ...